Wenche Stensen
Harstad, 9414, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.
Journal: Journal of medicinal chemistry
Published: April 20, 2026
Flexible and Biocompatible Antifouling Polyurethane Surfaces Incorporating Tethered Antimicrobial Peptides through Click Reactions.
Journal: Macromolecular bioscience
Published: September 18, 2023
Lateral membrane organization as target of an antimicrobial peptidomimetic compound.
Journal: Nature communications
Published: December 23, 2022
DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer's Disease-Down Syndrome Phenotypes.
Journal: Frontiers in pharmacology
Published: February 22, 2022
Anti-Colonization Effect of Au Surfaces with Self-Assembled Molecular Monolayers Functionalized with Antimicrobial Peptides on S. epidermidis.
Journal: Antibiotics (Basel, Switzerland)
Published: November 28, 2021
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 08, 2021
Lactoferricin-inspired peptide AMC-109 augments the effect of ciprofloxacin against Pseudomonas aeruginosa biofilm in chronic murine wounds.
Journal: Journal of global antimicrobial resistance
Published: June 03, 2021
In vitro and in vivo antibacterial properties of peptide AMC-109 impregnated wound dressings and gels.
Journal: The Journal of antibiotics
Published: November 03, 2020
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
Journal: Journal of medicinal chemistry
Published: October 14, 2016
Short Cationic Antimicrobial Peptides Display Superior Antifungal Activities toward Candidiasis and Onychomycosis in Comparison with Terbinafine and Amorolfine.
Journal: Molecular pharmaceutics
Published: September 01, 2016
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.
Journal: Journal of medicinal chemistry
Published: March 17, 2016
Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
Journal: European journal of medicinal chemistry
Published: December 19, 2014
Last Updated: 09/26/2026